A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Recruiting now · Phase 1/Phase 2
Conditions studied: Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC), Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), Neuroendocrine Carcinomas (NEC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
In brief
This is a first-in-human, Phase 1/2, open-label, dose escalation, dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Peluntamig (PT217) as a monotherapy and in combination with chemotherapy.
Key facts
- Study ID
- NCT05652686
- Run by
- Phanes Therapeutics
- People needed
- 203
- Starts
- 2023-09-05
- Expected to finish
- 2028-08-01
- Last updated by the study team
- 2026-07-15
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Providence Portland Medical Center — Portland, Oregon, United States (enrolling)
- Mays Cancer Center / University of Texas, San Antonio — San Antonio, Texas, United States (enrolling)
- NEXT Virginia — Fairfax, Virginia, United States (enrolling)
- Fred Hutch Cancer Center — Seattle, Washington, United States (enrolling)
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center) — Duarte, California, United States (enrolling)
- USC Norris Comprehensive Cancer Center — Los Angeles, California, United States (enrolling)
- Sarah Cannon Research Institute at HealthONE — Denver, Colorado, United States (enrolling)
- Yale University Cancer Center — New Haven, Connecticut, United States (enrolling)
- Sidney Kimmel Comprehensive Cancer Center at John Hopkins — Baltimore, Maryland, United States (enrolling)
- Massachusetts General Hospital — Boston, Massachusetts, United States (enrolling)
- Dana-Farber Cancer Institute — Boston, Massachusetts, United States (enrolling)
- Washington University School of Medicine (Siteman Cancer Center) — St Louis, Missouri, United States (enrolling)
- University of North Carolina at Chapel Hill — Chapel Hill, North Carolina, United States (enrolling)
- Duke University Medical Center — Durham, North Carolina, United States (enrolling)
- Sarah Cannon Research Institute University of Oklahoma — Oklahoma City, Oklahoma, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.